Scalper1 News
Fund holdings, ETF investing “}); $$(‘#article_top_info .info_content div’)[0].insert(bottom: $(‘mover’)); } $(‘article_top_info’).addClassName(test_version); } SeekingAlpha.Initializer.onDOMLoad(function() setEvents();); The Supreme Court has ruled 6-3 to uphold a key provision of the Affordable Care Act. The Supreme Court ruling holds that the Affordable Care Act can authorize federal tax credits for eligible Americans living not just in states with their own exchanges but also in the states that use the federal market place. This decision is not only a major win for the Obama Administration, it is also a win for healthcare companies. After the announcement, the S&P 500 healthcare index rose .85 percent and many hospital stocks enjoyed gains of 8 percent and above. These reactions from the market, show that Wall Street views the Supreme Court decision as a positive sign for the continuance of strong growth in the healthcare sector. With this Supreme Court decision and the historical steadiness of the healthcare sector, it would be wise to consider investing in this sector or increasing your investment exposure. Below we will share with you 3 buy-ranked healthcare mutual funds. Each has earned either a Zacks Mutual Fund Rank #1 (Strong Buy) or a Zacks Mutual Fund Rank #2 (Buy) as we expect these mutual funds to outperform their peers in the future. Fidelity Select Medical Delivery Portfolio (MUTF: FSHCX ) seeks long-term capital growth. FSHCX invests a major portion of its assets mainly involved in operations related to hospitals, nursing homes and other organizations engaged in providing healthcare services. FSHCX primarily focuses on acquiring common stocks of companies throughout the globe. Factors including financial strength and economic conditions are considered to invest in a company. The Fidelity Select Medical Delivery Portfolio fund is non-diversified and has returned 17.1% in the year-to-date frame. FSHCX has an expense ratio of 0.79% as compared to a category average of 1.37%. Turner Medical Sciences Long/Short C (MUTF: TMSCX ) invests a large chunk of its assets in healthcare firms. TMSCX uses a long/short growth strategy for reduction of volatility and capital preservation during market downturns. TMSCX mainly focuses on acquiring securities of companies having market capitalizations greater than $250 million. TMSCX is expected to maintain a portfolio of 15 to 75 securities long, and 15 to 75 securities short. The Turner Medical Sciences Long/Short C fund has returned 27.6% in the year-to-date frame. As of May 2015, TMSCX held 40 issues with 4.96% of its assets invested in Prothena Corp. pls (NASDAQ: PRTA ). Janus Global Life Sciences D (MUTF: JNGLX ) seeks capital appreciation over the long run. JNGLX invests the lion’s share of its assets in securities of life science oriented companies. JNGLX invests a minimum of one-fourth of its assets in firms from the “life sciences” domain. The Janus Global Life Sciences D fund has returned 21.8% in the year-to-date frame. Andrew Acker is the fund manager and has managed JNGLX since 2007. Original Post Share this article with a colleague Scalper1 News
Scalper1 News